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To determine the mechanism by which naltrexone (NTX) reduces oral 
ethanol-reinforced responding, opioid antagonists that show p-, K-, 
or &selectivity were evaluated. Rhesus monkeys (n = 6) were given 
opportunities to respond and receive ethanol (1'%0 or 2%) or water 
during daily 3-hr drinking sessions. Before some drinking sessions, 
the monkeys received intramuscular injections of saline or the fol- 
lowing drugs: the p-selective irreversible antagonist clocinnamox 
(CCAM), the K-selective long-lasting antagonist nor-binaltorphimine 
(nor-BNI), or the &selective antagonist naltrindole. Also, NTX was 
administered along with either CCAM or nor-BNI. When given alone, 
CCAM (0.1 mg/kg) had no effect on ethanol-reinforced responding. 
When NTX (0.32 mg/kg) was given with CCAM, responding main- 
tained by ethanol was decreased. Nor-BNI (3 mg/kg) reduced 
ethanol-reinforced responding only on the day of injection. On sub- 
sequent days, when other studies report continued K-antagonism, 
responding maintained by ethanol returned to control levels. Also, 
NTX (0.32 mg/kg), administered in the presence of nor-BNI, was still 
able to reduce ethanol-reinforced responding. Naltrindole failed to 
alter responding maintained by ethanol. Because selective antago- 
nism at the p-, K-, or &receptor did not reduce ethanol-reinforced 
responding, NTX's ability to reduce ethanol consumption may not be 
mediated by these previously characterized opioid receptors. NTX 
may exert its effects through an uncharacterized opioid binding site 
or through a nonopioid mechanism. 
Key Words: Alcohol, Naltrexone, Drinking, Opioids, Receptors. 
H E  OPIOID antagonist, naltrexone (NTX), has been T effective in reducing craving and relapse rates in clini- 
cal studies with alcohol-dependent patients.'92 In one of the 
studies, patients who failed to remain abstinent reported 
that the subjective "high" produced by alcohol consump- 
tion was reduced while on NTX.3 One hypothesis suggests 
that alcohol consumption increases activation of the endog- 
enous opioid system.435 Thus, NTX may produce its clinical 
effects by blocking this ethanol-induced opioid activity. 
Opioid antagonists reduce ethanol consumption in a se- 
lective and dose-dependent manner. In a previous study: 
we found that ethanol-reinforced responding was reduced 
dose-dependently by NTX. An antagonist similar to NTX, 
naloxone, selectively reduced ethanol consumption in High 
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Alcohol Drinking rats when water was also a~a i l ab le .~  In 
that study, low doses were effective (0.075 and 0.1 mglkg), 
but higher doses (1 to 18 mg/kg) were even moreso. Evi- 
dence suggests that, at very low doses, naloxone selectively 
occupies preceptors, while at larger doses, naloxone also 
occupies 6- and K-receptors.8-'o Thus, the reductions in 
alcohol drinking may be related to naloxone's binding prop- 
erties at p-receptors. 
Some research suggests that it may be possible to dlfferen- 
tiate the opioid receptor subtype through which naloxone or 
NTX reduces alcohol consumption. The Gantagonist, ICI 
174,864, was shown to reduce alcohol consumption selectively 
in rats when alcohol was available concurrently with water.'' 
The Gantagonist, naltrindole, had similar effects. However, 
one study demonstrated that ICI 174,864 did not affect alco- 
hol drinking, whereas CTOP, the p-antagonist, reduced 
alcohol, without affecting water or food intake.I3 The 
y-antagonist, p-funaltrexamine, has also been reported to 
reduce alcohol consumption selectively on the day of injec- 
tion, as well as on the day after the antagonist inje~ti0n.l~ This 
finding is in agreement with data that show p-funaltrexamine 
to be a long-duration irreversible antagonist at the 
~.l.-receptor.'~ Together, these studies suggest that the 6 or 
preceptor may be involved in the ethanol consumption- 
decreasing effects of naloxone or NTX. 
The p-selective irreversible antagonist, clocinnamox 
(CCAM), can be used to discriminate between opioid ag- 
onist effects at the preceptor and the 6- or K-receptor.I6 In 
food-reinforced rhesus monkeys, CCAM (0.1 mglkg) an- 
tagonized the rate-suppressant effects of y-agonists but not 
6- or ~-agonis ts . '~  In the warm-water tail withdrawal an- 
tinociception assay performed in rhesus monkeys, CCAM 
(0.1 mglkg) both reduced the potency of and suppressed 
the maximum antinociceptive effect of the potent 
pagonist, alfentanil." In that study, the number of 
preceptors available to interact with alfentanil was de- 
creased by CCAM, and full recovery was observed 2 to 4 
weeks later. In mice and rats, CCAM blocked both the 
analgesic effects and binding of preceptor agonists for 
days to weeks.'9320 These studies indicate that CCAM is a 
long-lasting and irreversible opioid antagonist with selec- 
tivity for the p-receptor in mice, rats, and monkeys. 
Other selective antagonists can be useful for discriminat- 
ing effects at the K- or  &receptor. For example, nor- 
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binaltorphimine (nor-BNI) is a K-selective antagonist with 
a long duration of action.21 One using the warm- 
water tail withdrawal assay in monkeys, found nor-BNI (3.2 
mgkg) to reduce the potency of K-selective agonists, but 
not agonists selective for other opioid receptors. Similar to 
CCAM, nor-BNI’s effect persisted for several (17 to 35) 
days. Another useful research tool, naltrindole (NTI), is an 
opioid antagonist selective for the &receptor. Using rhesus 
monkeys responding for food, Negus et al.23 examined 
whether NTI could antagonize the reduced responding 
caused by various opioid agonists. They showed that NTI (1 
and 3.2 mgkg) completely reversed the rate-decreasing 
effect produced by the 6-agonist BW373U86. NTI (3.2 
m a g )  had no effect when rates of food-maintained re- 
sponding were suppressed by p- and K-agonists. These 
studies provide evidence for the receptor-selective nature 
of nor-BNI and NTI for the K- and &receptors, respec- 
tively, in rhesus monkeys. 
The purpose of this study was to use p-, K-, or 6-selective 
opioid antagonists to determine the mechanism by which 
NTX reduces ethanol-reinforced responding in rhesus 
monkeys. Because CCAM and nor-BNI antagonist effects 
continued for a long time in the antinociceptive assays in 
monkeys, these drugs should be effective in reducing 
ethanol-reinforced responding for several days if the p -  
and/or K-receptor is involved in ethanol-reinforced re- 
sponding. In addition, if NTX is acting through p- or 
K-receptors to suppress ethanol-maintained responding, 
NTXs potency to reduce consumption may be reduced by 
prior administration of CCAM or n0r-BN1.*~ Using these 
selective antagonists alone and in conjunction with NTX 
may help to determine the opioid receptor through which 
NTX produces its alcohol consumption-decreasing effects. 
MATERIALS AND METHODS 
Subjects 
Subjects were 6 adult male rhesus monkeys (Mucuca muluttu; weighing 
6.3 to 9.9 kg) maintained at -80% of their free-feeding weights. In these 
experiments, the “Guide for the Care and Use of Laboratory Animals” 
(NIH publication, vol. 25, no. 28, revised 1996) was followed. 
Apparatus 
The animal housing room was on a 12-hr light/dark cycle (lights on at 
0700 hr, lights off at 1900 hr). The monkeys were housed in individual 
cages measuring 64 cm X 72 cm X 85 cm high. A fluid-delivery panel, 
similar to that used in other was attached to one wall of each 
cage during daily sessions. Holes were cut in the cage wall so that two brass 
spouts on the fluid-delivery panel protruded into the cage 50 cm from the 
floor. A stimulus light that could be illuminated red or green was located 
3 cm above each spout. The drinking solutions were contained in lo00 ml 
plastic bottles attached to the back of the panel. Plastic tubing connected 
each bottle to the spout valve. The fluid containers were elevated so that 
the liquid was gravity-fed to the spout valve and delivery was controlled by 
a solenoid switch. Contact with either spout closed an electrical circuit 
(drinkometer), and a response was recorded. The stimulus light above the 
spout flashed the appropriate color (green or red, depending on the fluid 
available) when contact was made with the spout. When the reinforcement 
schedule was satisfied, the solenoid was activated, and 0.5 ml of fluid was 
delivered. Solutions were measured after the session using graduated 
cylinders to confirm delivery amounts. The experiments were controlled 
and data recorded using IBM PCjr microcomputers located in a room 
adjacent to the housing room. 
Procedure 
Experimental sessions were conducted each day. Each session lasted 3 
hr, during which the animal could respond and obtain either ethanol or 
concurrently available water. Ethanol was available under the green stim- 
ulus light, and water was available under the red stimulus light. The 
monkeys were reinforced with 0.5 ml of fluid for every four mouth contacts 
on the spout (reinforcement schedule = fixed-ratio 4). The reinforcement 
schedule on each of the two spouts operated concurrently and indepen- 
dently such that the responses on one spout did not alter the number of 
responses required on the opposite spout. Water was always available 
during the session from one of the spouts. The animals were fed after the 
session. 
The opioid antagonists were administered while the monkeys had 
access to ethanol concentrations that maintained the greatest amount of 
responding. Three monkeys were responding and receiving 1% ethanol, 
and three were responding and receiving 2% ethanol. Due to the similar- 
ity, these data were pooled to obtain the average fluid deliveries and 
ethanol intake (g/kg). 
Injections of saline, NTX, nor-BNI, and NTI were each given 30 min 
before sessions during which ethanol was available concurrently with 
water. CCAM was given 4 hr before these sessions. CCAM (0.1 m a g )  
was given to each monkey four times, each separated by at least 2 weeks. 
Saline was given 3.5 hr after the first and third CCAM pretreatments, and 
NTX (0.32 m a g )  was given 3.5 hr after the second and fourth CCAM 
pretreatments. Nor-BNI (3 m a g )  was given twice to each monkey, each 
injection separated by -3 weeks. Six days after the first administration of 
nor-BNI, NTX (0.32 m@g) was administered along with nor-BNI. NTI (1 
and 3.2 mgkg) was given twice to each animal separated by 5 to 8 days. 
Saline pretreatments were also given frequently before and after admin- 
istration of nor-BNI, NTI, or NTX. For three monkeys, the antagonist 
order was CCAM, nor-BNI, then NTI. The other monkeys were tested 
first with NTI, CCAM, then NTI. Approximately 1.5 to 2 months of 
noninjection baseline and saline-pretreated sessions intervened between 
the different antagonist pretreatments. 
Data Analysis 
Each monkey’s average data (fluid deliveries, intake in f ig ,  and fluid 
deliveries expressed as percent of noninjection baseline) were used to 
calculate the mean and standard error of the mean for the group of 
monkeys. Data are presented as the mean and standard error of the mean 
of the group data (n = 6 monkeys). 
The fluid delivery data for the CCAM and nor-BNI pretreatments were 
analyzed together using a two-way repeated measures analysis of variance 
(RM ANOVA) testing for an effect of treatment, as well as an interaction 
of solution and treatment. The fluid-delivery data for the NTI pretreat- 
ments were analyzed in a similar manner. A one-way RM ANOVA was 
used to analyze the ethanol intake data for the CCAM and nor-BNI 
pretreatments. Ethanol intake for the NTI pretreatments was analyzed in 
a similar manner. For data expressed as a percent of noninjection baseline 
control, a one-way RM ANOVA on the ranks (Friedman test) was applied 
to the CCAM, nor-BNI, and NTI data. NTX data were from a previous 
study with different subjects: and thus were not compared statistically to 
the CCAM, nor-BNI, or NTI data. However, NTX data were previously 
analyzed using a one-way RM ANOVA. When significant differences 
were detected in any of the aforementioned tests, a post-hoc Student- 
Newman-Keuls test (SNK) was applied. For the results of all statistical 
analyses, significance refers t o p  < 0.05. 
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Fig. 1. (lop panel) Average number of fluid deliveries of ethanol (open and 
solid bars) and concurrently available water (lined bars) after different pretreat- 
ments: noninjection baseline, saline, 0.1 mg/kg of CCAM, and 0.1 mg/kg of 
CCAM followed by 0.32 mg/kg of NTX. (Bottom panel) Average ethanol intake 
(g/kg) after the same pretreatments. Bars represent the average with the standard 
error (n = 6 monkeys; 3 consuming 1 % ethanol and 3 consuming 2% ethanol). 
* Significant difference (p < 0.05) from saline. 
Drugs 
Ethanol solutions were prepared by mixing the appropriate volumes of 
95% w/v ethanol and tap water. NTI (provided by K. Rice, NIH), C C A M  
(provided by J. Lewis, Bristol University, UK), nor-BNI (provided by H. 
Mosberg, University of Michigan), and NTX (provided by the National 
Institute on Drug Abuse Research Technology Branch) were dissolved in 
sterile water. 
RESULTS 
Over all three experiments, the ethanol solution main- 
tained a greater number of fluid deliveries than did con- 
currently available water. During the first part of the ex- 
periment (CCAM administration), the average number of 
ethanol fluid deliveries for noninjection baseline was 934 
(+223), whereas the average after saline pretreatment was 
828 (2262). The average number of water deliveries during 
noninjection baseline was 67 ( 2  15), whereas the average 
after saline pretreatment conditions was 48 ( 2  17). These 
averages remained similar throughout the different antag- 
onist pretreatments. 
When CCAM (0.1 m a g )  was administered followed by 
saline injections, ethanol fluid deliveries and ethanol intake 
(g/kg) were similar to those shown during noninjection and 
saline injection controls (Fig. 1). When NTX (0.32 mgikg) 
was given after CCAM, the number of ethanol fluid deliv- 
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Fig. 2. (Top panel) Average number of fluid deliveries of ethanol (open and 
solid bars) and concurrently available water (lined bars) after different pretreat- 
ments: noninjection baseline, saline, 3 mg/kg of nor-BNI, the day after nor-BNI, 
and 0.32 mg/kg of NTX given 6 days after nor-BNI. (Bottom panel) Average 
ethanol intake (g/kg) after the same pretreatments. Bars represent the average 
with the standard error (n = 6 monkeys; 3 consuming 1% ethanol and 3 con- 
suming 2% ethanol). * Significant difference (p < 0.05) from saline. $ Significant 
difference from CCAM with NTX (in Fig. 1). 
[F(7,35) = 12.1; SNK q = 5.501, and ethanol intake (gikg) 
was also reduced [F(7,35) = 14.6; SNKq = 3.671. On the 
days subsequent to testing with CCAM followed by saline 
or CCAM followed by NTX, the ethanol fluid deliveries 
and ethanol intake (gikg) were no different from noninjec- 
tion and saline controls. Thus, CCAM alone had no effect 
on ethanol-reinforced responding, whereas NTX in the 
presence of CCAM decreased ethanol deliveries and intake 
on the day of administration. 
When compared with saline pretreatment, nor-BNI (3 
mglkg) significantly reduced the number of ethanol fluid 
deliveries [F(7,35) = 12.1; SNK q = 10.501 and ethanol 
intake (gikg) [F(7,35) = 14.6; SNK q = 8.301 (as shown in 
Fig. 2). However, on the days after nor-BNI, the ethanol 
fluid deliveries and intake (gikg) returned to levels similar 
to those during noninjection baseline or after saline pre- 
treatment. When NTX (0.32 mgikg) was given 6 days after 
nor-BNI, both the ethanol fluid deliveries and intake (gikg) 
were reduced (SNK q = 10.45 and 8.07). Ethanol fluid 
deliveries and intake (gikg) were unaffected on the days 
after NTX administration. Both nor-BNI alone and NTX 
given 6 days after nor-BNI reduced ethanol fluid deliveries 
below that of CCAM followed by NTX (SNK q = 5.40 and 
5.34). This effect was also observed for ethanol intake 
(gikg) (SNK q = 4.02 and 3.80). Thus, nor-BNI had an 
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Fig. 3. (Top panel) Average number of fluid deliveries of ethanol (open and 
solid bars) and concurrently available water (lined bars) after different pretreat- 
rnents: noninjection baseline, saline, 1 mg/kg of NTI, and 3.2 mg/kg of NTI. 
(Bottom panel) Average ethanol intake (g/kg) after the same pretreatments. Bars 
represent the average with the standard error (n = 6 monkeys; 3 consuming 1 ‘Yo 
ethanol and 3 consuming 2% ethanol). 
effect only on the day of injection and NTX after nor-BNI 
reduced ethanol-reinforced responding. Also, nor-BNI 
alone and NTX after nor-BNI showed the greatest potency 
in reducing ethanol-reinforced responding. 
NTI (1 and 3.2 mgkg), shown in Fig. 3, failed to reduce 
ethanol or water fluid deliveries [F(3,15) = 1 . 3 5 ; ~  < 0.301. 
Consequently, ethanol intake (g/kg) was unaffected as well 
[F(3,15) = 0 . 3 6 ; ~  < 0.781. 
To make a better comparison across antagonist pretreat- 
ments, the ethanol fluid deliveries were converted to a 
percent of noninjection baseline (Fig. 4). For comparison, 
the effects on NTX alone are also shown.6 From this pre- 
vious study, we found NTX (0.32 mgkg) alone had a 
significant effect. When NTX was given after CCAM ad- 
ministration, ethanol fluid deliveries were reduced, com- 
pared with sessions in which saline followed CCAM admin- 
istration [x2 (9) = 33.4; SNK q = 7.551. Compared with 
saline pretreatment, ethanol fluid deliveries were de- 
creased when either nor-BNI alone or nor-BNI with NTX 
was given before the session [SNK q = 7.10 and q = 6.66, 
respectively]. Also, nor-BNI alone and nor-BNI with NTX 
significantly reduced ethanol fluid deliveries more than the 
pretreatment of CCAM followed by NTX [SNK q = 4.91 
and q = 4.70, respectively]. Saline pretreatment during 
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Fig. 4. Average number of fluid deliveries for ethanol, expressed as a percent 
of noninjection baseline control over various treatments. For comparison, the far 
left panel shows the effects of NTX (saline: 0.1 rngkg and 0.32 mg/kg) from a 
previous study. The rest of the panels (from left to right) show the effects of NTI 
(saline, 1 mg/kg, and 3.2 mg/kg), CCAM (saline, 0.1 rng/kg, and 0.1 mg/kg of 
CCAM followed by 0.32 mglkg of NTX), and nor-BNI (saline, 3 rngkg, day after 
nor-BNI, and 0.32 mg/kg of NTX 6 days after nor-BNI). For the NTX data, bars 
represent the average with the standard error (fl = 5 monkeys). The rest of the 
bars represent the average with the standard error (n = 6). On the NTX panel, 
asterisk indicates a significant difference from saline on that panel. On the other 
three panels, + indicates a significant difference from all saline pretreatments 
(during NTI, CCAM, and nor-BNI testing), whereas JI indicates a significant 
difference from CCAM with NTX. 
DISCUSSION 
This study used receptor-selective opioid antagonists to 
determine which opioid receptor subtype mediates NTX’s 
ability to decrease ethanol-reinforced responding. The 
p-antagonist, CCAM, failed to reduce ethanol-reinforced 
responding. Furthermore, NTXs ability to reduce ethanol- 
reinforced responding was maintained in the presence of 
CCAM. The K-antagonist nor-BNI, caused a reduction in 
ethanol-reinforced responding only on the day of nor-BNI 
injection. Given in the presence of nor-BNI, NTX contin- 
ued to reduce ethanol-reinforced responding. Lastly, we 
found that the 6-antagonist, NTI, had no effect on ethanol- 
or water-reinforced responding. 
The failure of CCAM to reduce ethanol-reinforced re- 
sponding suggests that p-selective antagonism does not 
result in suppression of ethanol’s reinforcing effects. This, 
in turn, indicates that NTXs antagonist activity at the 
p-opioid receptor is not responsible for NTXs effect on 
ethanol intake. In other studies with rhesus monkeys, 0.1 
mg/kg of CCAM effectively blocked the effects of 
p-agonists. This CCAM dose reduced the potency of and 
suppressed the maximum antinociceptive effect of 
p-agonist alfentanil for 7 to 14 days.18 CCAM also reduced 
the reinforcing potency of intravenously self-administered 
alfentanil for 24 hr.26 In monkeys responding for food, this 
same dose of CCAM decreased the rate suppressing effects 
of p-agonist fentanyl for at least 24 hr.22 These studies 
indicate that the CCAM dose used in these experiments 
was effectively blocking p-opioid receptors. It is possible, 
however, that the CCAM dose was too small to reduce oral 
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ethanol-reinforced responding. The fact that doses of NTX 
required to suppress ethanol drinking are larger than those 
required to antagonize p-opioid effects in other systems27 
suggests that, if NTX acts to suppress ethanol-reinforced 
responding or consumption through a p-opioid mechanism, 
it is on less sensitive p-opioid receptors, perhaps those that 
are less available to binding by CCAM. 
There is a lack of research concerning the effects of 
K-antagonists on ethanol consumption. Most research has 
focused on the role of K-receptors on consummatory be- 
haviors in general.28 Some studies report that nor-BNI 
reduces consumption of a variety of substances in ro- 
d e n t ~ . ~ ~ . ~ ’  In addition, nor-BNI antagonized K-opioid ef- 
fects for days and weeks in rhesus monkeys22 and pigeons.31 
In the current experiment, nor-BNI (3 mgkg) reduced 
ethanol-reinforced responding only on the day of injection. 
Because a nor-BNI blockade of K-receptors should have 
been maintained for a much longer time, the reduction in 
ethanol-reinforced responding presumably does not reflect 
a K-mediated effect. In addition, K-agonists do not produce 
positive-reinforcing effects.32 This evidence suggests that 
activity at the K-receptor may not be responsible for the 
ethanol consumption-decreasing effect of NTX. 
The short-lived reduction of ethanol-reinforced respond- 
ing by nor-BNI may be due to a NTX-like effect. Because 
nor-BNI consists of two joined NTX compounds, this NTX- 
like effect is not surprising. Interestingly, nor-BNI has been 
shown to produce a short-lived antagonism of morphine- 
induced analgesia in mice, followed by a delayed antago- 
nism of ~ - 0 p i o i d s . ~ ~  If nor-BNI’s acute antagonism of mor- 
phine is through the same mechanism as its acute 
suppression of ethanol-reinforced responding, then we may 
conclude that nor-BNI and NTX suppress ethanol- 
reinforced responding through a p-antagonist mechanism. 
Because the p-antagonist CCAM failed to modify ethanol- 
reinforced responding, CCAM, nor-BNI, and NTX may 
not be acting at the same type of preceptor. 
Although some research indicates that Gopioids mediate 
ethanol cons~mption,”.~~ our study fails to support this evi- 
dence. In our experiment, the &antagonist NTI did not de- 
crease ethanol-reinforced responding. The doses tested have 
been shown to antagonize the rate-suppressant effects of 
Gagonist, BW373U86, in monkeys responding and receiving 
food reinforcement.u In that study, NTI produced a reduc- 
tion in potency of the Gagonist. When NTI 10 m a g  or higher 
was administered alone, they found little effect on response 
rates. However, these large doses began to antagonize the 
effects of p-agonist alfentanil. Thus, to observe the effects of 
selective &antagonism, we only tested NTI doses up to 3.2 
m a g .  Our data indicate that the &receptor does not mediate 
ethanol-reinforced responding in monkeys. 
The results of this study and our previous study6 indicate 
that the effect observed with NTX on ethanol-reinforced 
responding in rhesus monkeys may not be entirely ex- 
plained by antagonist effects at the, p-, K-, or &receptor. If 
ethanol increases endogenous opioid activity and NTX re- 
duces ethanol reinforced-responding by blocking that opi- 
oid activity, then the ethanoUNTX interaction should dis- 
play some characteristics similar to that of an opioid 
agonist/competitive antagonist interaction. However, we 
previously demonstrated that the NTX effect was not sur- 
mountable by increasing the ethanol concentration (oral 
self-administration) or ethanol dose (intravenous self- 
administration). The NTX doses that affect ethanol- 
reinforced responding are much higher than those needed 
to antagonize exogenously administered opioid effects. 
Furthermore, pretreatment with the p-selective antagonist 
CCAM had no effect on ethanol-reinforced responding. 
These results do not appear congruent with the idea that 
NTX reduces ethanol consumption by blocking ethanol- 
induced p-opioid activity. 
NTX given in the presence of CCAM or nor-BNI pro- 
duced some interesting results. The CCAM-induced re- 
moval of preceptors might be expected to affect any NTX 
activity through these receptors. However, in the presence 
of CCAM, NTX suppressed ethanol-reinforced respond- 
ing. Previous demonstrated that the ap- 
parent affinity of p-agonists is the same before and after 
CCAM treatment, which indicates that the NTX apparent 
affinity may be unchanged as well. Thus, NTX may possess 
the same ability to compete for the receptor before and 
after CCAM treatment and therefore produce the same 
effect. The other interesting result was that, in the presence 
of nor-BNI, NTX reduced ethanol fluid deliveries to a 
greater extent than that observed with NTX alone (our 
previous study6) or NTX in the presence of CCAM. To 
produce this enhanced NTX effect, the competitive antag- 
onist action of nor-BNI may be increasing NTX availability 
to the site responsible for the consumption-decreasing ef- 
fect. 
NTX may be producing its effects via an opioid binding 
site other than those that have been characterized to date. 
Because some, but not all, opioid antagonists reduce etha- 
nol consumption, NTX may be exerting its effect through 
an uncharacterized recognition site. To characterize this 
proposed mechanism, it is necessary to categorize and 
rank-order opioid antagonists based on their potency to 
reduce ethanol consumption. By combining this behavioral 
classification with a systematic analysis of the antagonists’ 
binding properties for this presumed “NTX recognition 
site,” we may be able to discover if this site is distinct from 
the already characterized opioid binding sites. 
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